Rutin, a poorly absorbed plant compound sold as a dietary supplement and studied for blood vessel health, clotting and aging, has small, mostly indirect evidence: blood pressure and unconfirmed blood sugar improvements in type 2 diabetes come from one group, leg-vein relief from modified versions, aging effects from cells and mice. Side effects appear mild; added bleeding with anti-clotting medications is a practical concern. Effects in healthy people remain unproven. (Full Review)
| Marker | Target | Why |
|---|---|---|
| HbA1c | 4.0–5.6% | Expected to change (glycemic benefit) |
| Fasting glucose | 70–99 mg/dL | Expected to change; low-glucose safety check on diabetes drugs |
| Blood pressure (home, seated) | Below 120/80 mmHg | Expected to change; low-pressure safety check on blood pressure drugs |
| LDL cholesterol | No established target; change from own baseline | Expected to change (lipid benefit) |
| Serum creatinine with eGFR | Creatinine 0.6–1.3 mg/dL | Safety check (kidney toxicity) |
| Ferritin | About 24–336 ng/mL (men), 11–307 ng/mL (women) | Safety check (iron absorption) |
| INR (warfarin users only) | Clinician-set target on warfarin; 0.8–1.2 without anticoagulants | Safety check (bleeding or clotting on warfarin) |
Cadence: Baseline before starting; INR within one week of starting for warfarin users; daily home glucose and blood pressure for the first two to four weeks on diabetes or blood pressure drugs; repeat laboratory tests at three months, then every 6–12 months while rutin continues.